Life sciences marketing
built for MLR
In pharma the constraint is not creativity or budget — it is review. Programmes that ignore medical, legal and regulatory workflow die in approval queues. We build content systems and measurement that move through MLR rather than around it.
How pharma marketing differs structurally
Pharmaceutical marketing is constrained by mandatory medical, legal and regulatory review of every promotional asset, and by a hard separation between unbranded disease education and branded product promotion. Off-label discussion is prohibited, fair balance is required, and audience gating between healthcare professionals and the public is a compliance requirement rather than a targeting preference.
Two audiences that must not be mixed
Healthcare professionals and patients search the same conditions with completely different vocabulary, and the regulatory rules governing what each may be shown are different too.
HCP search behaviour is precise and evidence-led: mechanism of action, trial data, comparative efficacy, dosing, contraindications, guideline positioning. This audience is unimpressed by marketing language and reads primary literature. Content that summarises evidence accurately, cites trials properly and respects clinical nuance earns attention; content that reads like a brochure does not.
Patient and caregiver search is symptomatic and emotional, and in most jurisdictions may only be served unbranded disease education rather than product promotion. That separation is not a preference — it determines what content may exist on which properties, how gating works, and what may be said at all. Getting the architecture wrong is a regulatory problem, not a UX one.
Indicative effort distribution used in planning. Actual split depends heavily on jurisdiction — what is permitted in the US differs substantially from the EU and UK.
The HCP adoption pathway
Clinicians do not convert. They accumulate confidence across evidence, peers and guidelines, over months.
Encountering the unmet need
Usually through congress coverage, journal reading or a patient case that current options handle poorly. Unbranded disease-state education reaches this stage; product promotion does not yet register.
Interrogating the data
Trial design, endpoints, patient populations, statistical significance, safety profile. Accuracy and completeness matter more than emphasis. Overstating efficacy here loses the clinician permanently.
What are colleagues doing?
Key opinion leader positions, society guidance, peer discussion and real-world experience. Digital plays a supporting role — the primary influence is professional, not promotional.
Can I actually prescribe this?
Formulary status, prior authorisation burden, reimbursement, patient cost and administration logistics. Access barriers stop more adoption than clinical scepticism does.
First patients, then habit
Early prescribing experience determines whether use continues. Patient support programmes, adherence resources and access assistance materially affect whether initial trial becomes standing practice.
Where pharma digital programmes stall
The failure mode is almost never creative quality. It is process design.
Marketing built against the review process
- Assets designed first, then submitted to MLR and rebuilt from scratch
- Unbranded and branded content mixed on the same properties
- Claims written to maximum ambition, guaranteeing rejection cycles
- Congress content briefed six weeks out, missing the demand peak
- Measurement plans that would require tracking individual clinicians
- Agencies who treat MLR as an obstacle rather than a design input
Marketing built through the review process
- Claims matrix agreed with medical affairs before production begins
- Separate architecture and gating for unbranded and branded tracks
- Reference-linked assertions drafted to what the data supports
- Congress calendar driving a six-month content and demand plan
- Aggregate, de-identified measurement designed for the constraint
- Review timelines built into the schedule as a fixed cost, not a delay
Channels, and what governs each
Permitted activity varies sharply by jurisdiction and by whether the audience is professional or public.
| Channel | Job in the programme | Primary KPI | Governing constraint |
|---|---|---|---|
| Unbranded disease education | Build condition awareness and diagnosis rates | Qualified organic reach | No product reference of any kind |
| HCP evidence content | Support clinical evaluation with accurate data | HCP engagement depth | Full MLR approval; references linked |
| Gated HCP portals | Serve branded material to verified professionals | Verified HCP registrations | Audience verification is mandatory |
| Congress-cycle demand | Capture attention around scientific meetings | Session and content engagement | Plan around embargo and data release timing |
| Medical information SEO | Answer clinical questions accurately | Query coverage | Must route to medical information, not sales |
| Patient support resources | Improve access and adherence | Programme enrolment | Unbranded or approved support material only |
| Paid search (unbranded) | Reach undiagnosed and searching patients | Cost per qualified session | Platform pharma policy; no branded claims |
This table describes a general framework. Permitted activity differs materially between the US, EU, UK and other markets, and your regulatory affairs function is the authority on what applies to your products.
The constraints we design around
Your medical, legal and regulatory functions define these. This is how we build so that what reaches them is approvable.
On-label only
Promotional material may only reference approved indications, populations and dosing. Any content implying use beyond the label is out of scope regardless of how strong the supporting evidence appears.
Fair balance
Efficacy claims carry a corresponding obligation to present safety information with comparable prominence. Layouts are designed with that requirement built in rather than bolted on at review.
Audience gating
Where branded material may only reach healthcare professionals, verification is a regulatory requirement. Gating is designed into the architecture, not implemented as a checkbox interstitial.
Reference substantiation
Every assertion links to the specific study, guideline or label section supporting it. A maintained reference library is what makes rapid review possible instead of a fresh argument each cycle.
Market-by-market rules
What is permitted in the US differs substantially from the EU, UK and other markets — including whether branded public-facing communication may exist at all. Content is scoped by market from the outset.
Adverse event obligations
Any channel accepting user input can surface an adverse event report, triggering pharmacovigilance duties. Social and comment-enabled properties need monitoring and routing agreed before launch.
Regulatory authority stays with you
This summarises constraints we design around; it is not regulatory advice and does not substitute for your medical, legal and regulatory review. Every asset goes through your process, and we build assuming it will.
Measured without tracking clinicians
Individual-level HCP tracking is neither appropriate nor necessary. Aggregate engagement depth tells you what you need.
MLR cycle time is a growth metric
If review takes eleven weeks, no channel strategy compensates. Reducing it is often the highest-leverage available intervention.
Reuse beats production
An approved claims library that assembles into multiple assets outperforms commissioning each asset from scratch through review.
Aggregate, never individual
Engagement depth by content type and audience segment gives sufficient signal without individual-level clinician tracking.
Life sciences reporting line
- Verified HCP portal registrations
- Genuine professional audience growth
- Evidence content engagement depth
- Time and scroll on clinical material
- Unbranded reach in target conditions
- Disease-awareness programme performance
- Medical information query coverage
- Share of clinical questions answered
- Congress-window engagement lift
- Against baseline, per meeting
- Patient support enrolment
- Access programme uptake
- MLR cycle time
- Operational metric that gates everything else
- Approved asset reuse rate
- Efficiency of the content system
Built around the review calendar
The plan is scheduled backwards from MLR capacity and congress dates, because those are the fixed points.
Claims and constraint mapping
Work with medical affairs and regulatory to establish the approved claims matrix, reference library and jurisdictional boundaries. Nothing is produced before this exists — it is what prevents rebuild cycles.
Architecture separation
Unbranded and branded properties structured separately, with audience verification and gating designed to the regulatory requirement rather than retrofitted afterwards.
Modular content system
An approved component library — claims, references, visuals — that assembles into multiple assets. Each new asset draws on pre-approved modules, which is what shortens review cycles.
Congress-cycle programming
Content and demand planned around scientific meeting calendars and data release timing, with assets through review well before embargo lifts.
Measure and reduce cycle time
Aggregate engagement reporting alongside operational MLR metrics, with process improvement treated as a programme deliverable rather than an internal aside.
An honest statement of our position
Our life sciences work centres on digital infrastructure, content systems and search visibility — not medical affairs strategy, regulatory submissions or promotional review. We work alongside your medical, legal and regulatory functions and defer to them on every question of what may be claimed. If you need an agency to argue for more aggressive promotional positioning, we are not that partner.
We treat MLR as a design constraint to build around, in the same way a structural engineer treats load limits. Arguing with it is not a strategy.Oneskai life sciences engagement policy
Pharma & Life Sciences questions
What is MLR review and why does it dominate planning?
Medical, legal and regulatory review is the mandatory approval process every promotional pharmaceutical asset passes through before publication. Cycle times commonly run several weeks and rejections trigger rebuilds. Because it is a fixed constraint on throughput, planning that ignores it produces campaigns that miss their windows.
How do you separate unbranded and branded content?
Structurally, not cosmetically. Unbranded disease education lives on separate properties with no product reference, its own navigation and its own analytics. Branded material sits behind professional verification where required. The separation is built into information architecture from the start, because retrofitting it is expensive and risky.
Can you help reduce our MLR cycle times?
Indirectly and often substantially. Most cycle time is consumed by rework on claims that were never going to be approved. An agreed claims matrix and a pre-approved modular component library mean new assets assemble from approved parts rather than starting fresh, which shortens review considerably.
Is direct-to-consumer advertising possible?
It depends entirely on jurisdiction. Branded prescription advertising to the public is permitted in a small number of markets, notably the United States, under strict conditions including fair balance requirements. In most other markets, including the EU and UK, it is prohibited and only unbranded disease education is available.
How do you measure HCP engagement compliantly?
At aggregate level. We report engagement depth by content type, verified portal registrations, and query coverage across clinical topics — none of which requires tracking identifiable individual clinicians. That gives enough signal to allocate effort while staying well inside appropriate boundaries.
How far ahead should congress content be planned?
Around six months, driven backwards from the meeting date. Assets need to clear MLR before embargo lifts, demand peaks sharply and briefly around presentation dates, and the window closes quickly. Content briefed six weeks out reliably misses the peak it was created for.
Do you write medical or scientific content yourselves?
We build the content system, information architecture, search strategy and measurement. Scientific accuracy and clinical writing require medical writers accountable within your organisation or a specialist medical communications partner. We work alongside them rather than substituting for them.
Related capabilities
Sources & references
- US FDA, Office of Prescription Drug Promotion — guidance on promotional labelling and advertising.
- EFPIA Code of Practice on the promotion of prescription-only medicines and interactions with HCPs.
- ABPI Code of Practice for the Pharmaceutical Industry (UK market).
- Google Ads Help, healthcare and medicines policy — pharmaceutical advertising restrictions by market.
- Google Search Quality Rater Guidelines — YMYL standards applying to medical content.
- Schema.org, MedicalWebPage, Drug and MedicalStudy vocabulary specifications.
Start with the claims matrix
We map your approved claims, reference library and jurisdictional boundaries into a modular content system — so future assets assemble from pre-approved components instead of restarting review each time.